Protective efficacy of pregabalin to peripheral neuropathy induced by oxaliplatin or paclitaxel

Protective efficacy of pregabalin to peripheral neuropathy induced by oxaliplatin or paclitaxel - Protective efficacy of pregabalin to chemotherapy-induced neuropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006421

Enrollment

Registered

2011-10-01

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor

Interventions

Prebgabalin Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cancer patients who will be treated with oxaliplatin- or paclitaxel-based chemotherapy 2. Patients who can take pregabalin 3. Patients with written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with a history of oxaliplatin or paclitaxel chemotherapy 2. Patients with peripheral neuropathy 3. Patients treated with pregabalin 4. Patients with allergy history for pregabalin 5. Patients with cleatinine clearance of 30 mL/min or less

Design outcomes

Primary

Measure	Time frame
Incidence of peripheral neuropathy	—

Countries

Japan

Contacts

Public ContactKohji Naora

Shimane University Hospital Department of Pharmacy

knaora@med.shimane-u.ac.jp0853-23-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026